Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains.

Chalmet K, Van Wanzeele F, Demecheleer E, Dauwe K, Pelgrom J, Van Der Gucht B, Vogelaers D, Plum J, Stuyver L, Vandekerckhove L, Verhofstede C.

Virology. 2008 Sep 30;379(2):213-22. doi: 10.1016/j.virol.2008.06.036. Epub 2008 Aug 9.

2.

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.

3.

Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression.

Tang J, Rivers C, Karita E, Costello C, Allen S, Fultz PN, Schoenbaum EE, Kaslow RA.

Genes Immun. 1999 Sep;1(1):20-7.

4.

Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age.

Buseyne F, Janvier G, Teglas JP, Ivanoff S, Burgard M, Bui E, Mayaux MJ, Blanche S, Rouzioux C, Rivière Y.

J Infect Dis. 1998 Oct;178(4):1019-23.

PMID:
9806029
5.

Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection.

Sei S, Boler AM, Nguyen GT, Stewart SK, Yang QE, Edgerly M, Wood LV, Brouwers P, Venzon DJ.

AIDS. 2001 Jul 27;15(11):1343-52.

PMID:
11504955
6.

The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.

Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA.

Br J Haematol. 2000 Oct;111(1):136-42.

PMID:
11091193
7.

HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C, Fenyö EM.

AIDS. 2003 Dec 5;17(18):2561-9.

PMID:
14685050
8.

HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.

Walli R, Reinhart B, Luckow B, Lederer E, Loch O, Malo A, Wank R, Schlöndorff D, Goebel FD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):229-33.

PMID:
9665499
9.

[Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].

Wasik TJ, Smoleń J, Kruszyński P, Bratosiewicz-Wasik J, Beniowski M.

Wiad Lek. 2005;58(9-10):500-7. Polish.

PMID:
16529059
10.
11.

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):307-13. Review.

PMID:
11873082
13.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.

PMID:
18614865
14.

The influence of MT-2 tropism on the prognostic implications of the delta32 deletion in the CCR-5 gene.

Bratt G, Sandström E, Albert J, Samson M, Wahren B.

AIDS. 1997 Oct;11(12):1415-9.

PMID:
9342063
15.

Characterization of a third CCR5 amplicon from CCR5-delta32-heterozygous HIV-1-infected individuals.

Aikhionbare FO, Newman C, Womack C, Roth WW, Stringer HG Jr, Bond VC.

AIDS. 1999 Aug 20;13(12):1585-6. No abstract available.

PMID:
10465086
16.

Prevalence of mutant CCR5 allele in Slovenian HIV-1-infected and non-infected individuals.

Poljak M, Tomazic J, Seme K, Maticic M, Vidmar L.

Acta Virol. 1998 Feb;42(1):23-6.

PMID:
9645239
17.

Similar HIV-1 evolution and immunological responses at 10 years despite several therapeutic strategies and host HLA Types.

Arnedo-Valero M, Plana M, Mas A, Guilà M, Gil C, Castro P, Garcia F, Domingo E, Gatell JM, Pumarola T.

J Med Virol. 2004 Aug;73(4):495-501.

PMID:
15221891
18.

HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group.

Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, Sørensen AM, Garred P, Koppelhus U, Svejgaard A, Gerstoft J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):10-4.

PMID:
9377119
20.

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ.

Science. 1996 Sep 27;273(5283):1856-62. Erratum in: Science 1996 Nov 15;274(5290):1069.

PMID:
8791590

Supplemental Content

Support Center